Michael C. Soulen
Hepatology · 2000–2018
A researcher in the Science corpus: 5 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Hepatology — 18 citations into it
Whom Michael C. Soulen trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from Michael C. Soulen's perspective
Ordered by how strongly the researchers Michael C. Soulen trusts endorse each paper. Same corpus, a different order for every researcher.
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study (Cardiovascular and Interventional Radiology)
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. (The Lancet)
- Sorafenib in advanced hepatocellular carcinoma. (New England Journal of Medicine)
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival (Hepatology)
- Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma (Gastroenterology)
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma (Hepatology)
- CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia (Science Translational Medicine)
- Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells (Clinical Cancer Research)
Their papers
- Activity of Mesothelin-specific Chimeric Antigen Receptor T cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial (2018) — 427 citations
- Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data (2016) — 662 citations
- Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. (2014) — 921 citations
- Mesothelin-specific Chimeric Antigen Receptor mRNA-Engineered T cells Induce Anti-Tumor Activity in Solid Malignancies (2013) — 804 citations
- Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. (2000) — 615 citations